Trial Profile
An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 06 May 2022 Planned End Date changed from 27 Apr 2023 to 31 Dec 2024.
- 06 May 2022 Planned primary completion date changed from 27 Apr 2023 to 31 Dec 2024.
- 14 Dec 2018 Status changed from recruiting to active, no longer recruiting.